Notis McConarty Edward boosted its position in Novartis AG (NYSE:NVS) by 0.2% during the second quarter, Holdings Channel reports. The firm owned 34,975 shares of the company’s stock after buying an additional 72 shares during the period. Novartis AG accounts for 1.9% of Notis McConarty Edward’s investment portfolio, making the stock its 20th largest position. Notis McConarty Edward’s holdings in Novartis AG were worth $2,920,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Howe & Rusling Inc. raised its stake in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the period. City Holding Co. raised its stake in Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares during the period. TCI Wealth Advisors Inc. raised its stake in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the period. Archford Capital Strategies LLC raised its stake in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC raised its stake in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the period. Institutional investors own 11.27% of the company’s stock.

Shares of Novartis AG (NVS) traded up 0.22% on Friday, hitting $83.36. The stock had a trading volume of 920,198 shares. The firm’s 50-day moving average is $84.25 and its 200 day moving average is $78.58. The stock has a market cap of $195.30 billion, a P/E ratio of 30.43 and a beta of 0.73. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90.

Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s revenue was down 1.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 EPS. Equities analysts forecast that Novartis AG will post $4.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/11/notis-mcconarty-edward-raises-stake-in-novartis-ag-nysenvs.html.

A number of research firms have recently issued reports on NVS. BidaskClub lowered Novartis AG from a “hold” rating to a “sell” rating in a research note on Friday. Cowen and Company set a $90.00 target price on Novartis AG and gave the company a “hold” rating in a research note on Wednesday. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Monday, July 17th. Finally, Zacks Investment Research lowered Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.01% of the stock is owned by company insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.